CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: A multicenter study

Basit Öğe Kaydı
dc.authorid0000-0001-6826-7818
dc.authorid0000-0003-1237-8281
dc.contributor.authorDemirci, Ufuk
dc.contributor.authorKırkızlar, Hakkı Onur
dc.contributor.authorÜmit, Elif Gülsüm
dc.contributor.authorGürsoy, Vildan
dc.contributor.authorPınar, İbrahim Ethem
dc.contributor.authorÖzkalemkaş, Fahir
dc.contributor.authorGüven, Zeynep Tuğba
dc.contributor.authorKaynar, Leylagül
dc.contributor.authorKeklik Karadağ, Fatma
dc.contributor.authorSaydam, Güray
dc.contributor.authorEkinci, Ömer
dc.contributor.authorMerter, Mustafa
dc.contributor.authorAras, Merih Reis
dc.contributor.authorAlbayrak, Murat
dc.contributor.authorKaraman Gülsaran, Sedanur
dc.contributor.authorBaş, Volkan
dc.contributor.authorBalık Aydın, Berrin
dc.contributor.authorBeköz, Hüseyin Saffet
dc.contributor.authorCan, Ferda
dc.contributor.authorDilek, İmdat
dc.contributor.authorMehtap, Özgür
dc.contributor.authorÖztürk, Erman
dc.contributor.authorÇobanoğlu Şimşek, Bengü
dc.contributor.authorYıldırım, Murat
dc.contributor.authorAylı, Meltem
dc.contributor.authorAtaş, Ünal
dc.contributor.authorSalim, Ozan
dc.contributor.authorAyer, Mesut
dc.contributor.authorBirtaş Ateşoğlu, Elif
dc.contributor.authorAkay, Olga Meltem
dc.contributor.authorKurt Yüksel, Meltem
dc.contributor.authorPaydaş, Semra
dc.contributor.authorKorkmaz, Selçuk
dc.contributor.authorÖz Puyan, Fulya
dc.contributor.authorDemir, Ahmet Muzaffer
dc.date.accessioned2022-12-26T07:57:11Z
dc.date.available2022-12-26T07:57:11Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractDiffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and comprises a heterogeneous group of disease. While classification of B-cell lymphomas has been evolving to include clonality in a specific manner, morphology, and immunohistochemistry remain the backbone. We aimed to evaluate the value of CD5 expression on disease characteristics as well as prognosis in patients with DLBCL. Data of 131 patients with DLBCL with CD5 positivity and as a comparison arm, data of 129 patients with DLBCL without CD5 positivity were evaluated. Mean age was 59 and 55.7% of the patients were male. Overall survival was 29.8 months. Poor prognostic factors including (high-LDH levels, B symptoms, low ECOG score, high R-IPI and NCCN-IPI score) were observed to be significantly related with CD5 positivity. Mean survival in CD5 positive patients were 29.8 months, which is significantly shorter than the general DLBCL survival worldwide. CD5 expression shall be evaluated in all samples of DLBCL patients due to its possible effects on outcomes.
dc.identifier.citationDemirci, U., Kırkızlar, H. O., Ümit, E.G., Gürsoy, V., Pınar, İ. E., Özkalemkaş, F. ... Demir, A. M. (2022). CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: A multicenter study. Journal of Hematopathology, 15(4), 203-213. https://doi.org/10.1007/s12308-022-00523-6
dc.identifier.doi10.1007/s12308-022-00523-6
dc.identifier.endpage213
dc.identifier.issn1868-9256
dc.identifier.issn1865-5785
dc.identifier.issue4
dc.identifier.scopus2-s2.0-85143634789
dc.identifier.scopusqualityQ4
dc.identifier.startpage203
dc.identifier.urihttps://doi.org/10.1007/s12308-022-00523-6
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10179
dc.identifier.volume15
dc.identifier.wos000905040100001en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorBalık Aydın, Berrin
dc.institutionauthorBeköz, Hüseyin Saffet
dc.language.isoen
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.relation.ispartofJournal of Hematopathologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectc-MYC
dc.subjectCD 5
dc.subjectCNS Prophylaxis
dc.subjectDiffuse Large B-cell Lymphoma
dc.subjectDouble/Triple Expressor
dc.titleCD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: A multicenter study
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu